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Abstract
Immunotoxins are hybrid molecules that generally consist of a toxin
coupled with a tumor-specific antibody or antibody fragment that is
intended to target and concentrate the toxin within the tumor
tissue. The biodistribution, specificity, immunogenicity, and cytotoxic
activity of the immunotoxin are but a few of the factors that govern
the effectiveness of these compounds in the treatment of patients
with cancer. Improvements in design, synthesis, and delivery of
these molecules may permit them to become significant
components in the arsenal of targeted therapies for cancer.
In this issue of Breast Cancer Research, von Minckwitz and
colleagues [1] report the results of phase I study conducted
in patients with advanced cancer using ScFv(FRP5)-ETA, a
recombinant, single chain (sc) antibody toxin with binding
specificity for HER2 [2,3] linked to Pseudomonas exotoxin A
(ETA). Although significant clinical responses were not
observed, ScFv(FRP5)-ETA appeared to be well tolerated at
dose levels that may prove clinically active. As such,
ScFv(FRP5)-ETA joins a growing list of promising new
agents in targeted therapy for solid tumors.
The notion of targeted tumor killing is has been around since
early in the past century. In 1906, Ehrlich [4] introduced the
concept of targeting cancer cells with a ‘magic bullet’,
consisting of tissue-specific carriers that would deliver toxic
agents to neoplastic tissue. The advent of mAbs made it
possible to generate virtually unlimited amounts of antibody
specific for antigens that are differentially expressed by tumor
cells versus their normal cell counterparts. Although examples of
truly tumor-specific antigens are rare, it is often possible to find
tumor-associated antigens that are restricted in their tissue
distribution or that are expressed at aberrantly high levels by
tumor cells. A prime example of the latter is HER2/neu, a
surface protein that is over-expressed by many types of cancers,
in particular adenocarcinoma of the breast [5-7]. As such,
HER2/neu is an attractive target for antibody-directed therapies.
In fact, the first mAb approved for the use in solid tumor
therapy was Herceptin, a humanized mAb specific for HER2.
It is currently used in the treatment of breast cancer as
monotherapy or in combination with chemotherapeutic
agents. Although remarkable objective responses were
observed, only a fraction of patients experienced a complete
response and/or a long-lasting response with this mAb
[8-11]. In addition, side effects such as cardiac dysfunction
have been observed, the incidence and severity of which
appears to be greatest in patients receiving Herceptin in
combination with anthracyclines [12].
It is conceivable that linking antibodies to HER2/neu with
drugs and/or toxins might generate immunotoxins with
different mechanisms of action [13,14]. This approach may
have lower toxicity because the toxic agent is anticipated to
concentrate in and around the tumor, leading to higher local
concentrations. Initially, antibodies were conjugated to
radioisotopes. Most immunotoxins currently contain modified
plant, bacteria, or fungi toxins. The two most commonly used
bacterial toxins are diphtheria toxin and Pseudomonas
exotoxin [15]. An advantage of this approach is that, through
selective delivery of drugs to tumors, it can reduce systemic
toxicity. One single immunotoxin can kill a tumor cell, whereas
105 molecules of a chemotherapeutic drug are needed to
achieve the same effect [16].
Another problem that may be circumvented by immunotoxins
is that of poor penetration of antibody molecules into some
tumor tissues. Through the use of antibody fragments, such
as the scFv used by ScFv(FRP5)-ETA, immunotoxins with
sizes smaller than antibody molecules can be generated that
may achieve more effective penetration of solid tumor tissue
than whole antibody molecules [17,18].
von Minckwitz and colleagues [19] previously reported that
injection of ScFv(FRP5)-ETA into cutaneous nodules of tumor
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cells that over-express HER2/neu caused shrinkage or
complete regression of the injected tumor nodules in most
treated patients. To develop this into a systemic therapy,
those investigators examined the toxicity of intravenous
injections of ScFv(FRP5)-ETA in a phase I dose escalation
study including 18 patients with advanced cancers that over-
expressed HER2/neu. When administered daily as an intra-
venous bolus infusion over 5 days every 2 weeks, the investi-
gators found that doses of 12.5 µg/kg were well tolerated.
Peak plasma concentrations of ScFv(FRP5)-ETA in patients
treated at this dose level generally were greater than
100 ng/ml – a level that apparently has activity against tumor
cells in vitro.
On the other hand, 13 out of the 18 patients treated
generated antibodies against ScFv(FRP5)-ETA, which in five
cases apparently could neutralize the activity of this
immunotoxin. Such antibodies certainly could diminish the
plasma concentration of ScFv(FRP5)-ETA with repeated use.
Conceivably, the generation of similar immunotoxins
containing humanized antibody fragments instead of the
mouse anti-HER2/neu antibody fragment could help to
mitigate this problem by reducing the tendency for inducing
antibodies – that could accelerate the clearance of the
immunotoxin and/or inhibit its ability – to bind selectively to
their intended tumor target [20].
In any case, on the surface it appears that ScFv(FRP5)-ETA
is better tolerated than another Fv immunotoxin directed
against HER2/neu, namely erb-38 [21]. The latter
immunotoxin combines the same toxin with an anti-HER2/neu
Fv via a disulphide bond. However, erb-38 had hepatoxicity
apparently at lower doses in phase I testing, an effect that is
not completely understood [18]. Unlike erb38, the mAb FRP5
does not bind to liver cells, minimizing the cross-reactivity
with normal tissue. This could explain the relatively low toxicity
of the agent [19]. However, von Minckwitz and colleagues [1]
point out that even in mouse models, in which binding to
endogenous HER2 on liver cells can be excluded, erb-38 is
still more toxic than ScFv(FRP5)-ETA. Another possibility is
that the liver toxicity caused by erb-38 could be due to
different clearance in the liver, the binding stability of the toxin
moiety, or the difference in the binding epitopes of the two
antibodies. These differences should be further explored
because a more resilient immunotoxin that lacks systemic
toxicity would be very desirable. Such an agent could be
administered via continuous infusion to maintain a constant
plasma concentration, which might permit optimal perfusion
into the tumor mass.
In conclusion, ScFv(FRP5)-ETA is an immunotoxin that is
composed of a potent toxin combined with a recombinant
single-chain antibody toxin with binding specificity for
HER2/neu. Prior studies indicated that direct injection of this
immunotoxin into subcutaneous nodules of tumor cells over-
expressing HER2/neu could induce local tumor regression.
To develop ScFv(FRP5)-ETA for systemic therapy, von
Minckwitz and colleagues [1] evaluated the safety of
administering this immunotoxin intravenously to patients with
HER2/neu over-expressing cancers. Although clinical
responses were modest at best and antibodies against
ScFv(FRP5)-ETA developed in most of the treated patients,
the study found that ScFv(FRP5)-ETA could be administered
intravenously to patients at doses that may have clinical
activity without major hepatic toxicity. Although more clinical
studies are necessary, it is conceivable that ScFv(FRP5)-ETA
may find utility in the targeted therapy of solid tumors.
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